The short half-life means drug accumulation from a double dose can cause severe GI side effects
"There are some older-generation drugs that are safe and effective and are still in use," says Dr
doi: 10.1111/1753-0407.12891 Summary Keywords diabetic kidney disease, diabetic nephropathy, GLP-1 receptor agonists, liraglutide, semaglutide, dulaglutide Citation Kawanami D and Takashi Y (2020) GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
Szpunar for her help in creating Table 2 and A
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
Consequently, we wonder how gutderived GLP1 activates GLP1 release from the brainstem PPG neurons